Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Coya Therapeutics, Inc. (COYA)

Coya Therapeutics Q3 net loss widens to $10.6 million on lower revenue

Negative Impact 3 of 5 earnings

Coya Therapeutics reported a third-quarter 2026 net loss of $10.6 million, up from $2.1 million a year earlier, as collaboration revenue fell to $0.2 million from $3.6 million and research and development expenses rose to $8.6 million. The company said enrollment is complete in its Phase 2/3 ALSTARS trial of COYA 302 for ALS, with topline data expected in early Q2 2027, and that its $35.8 million in cash is sufficient into the second half of 2027.

Key points

  • Net loss of $10.6 million for the quarter ended September 30, 2026, versus $2.1 million a year earlier
  • Collaboration revenue of $0.2 million, down from $3.6 million in the prior-year quarter, which included a $3.3 million license recognition
  • Research and development expenses rose to $8.6 million from $2.9 million, mainly due to the COYA 302 ALS Phase 2/3 trial
  • Cash and cash equivalents of $35.8 million as of September 30, 2026; topline ALSTARS data expected early Q2 2027

The filing

CompanyCoya Therapeutics, Inc. (COYA)
Form8-K, current report
Filed with the SECNov 10, 2026, 8:02 AM ET
Accession number0001193125-26-454473

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 8:23 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.